Compare Gilead Sciences, Inc. (GILD) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while abrdn Physical Palladium Shares ETF trades at $23.09. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while abrdn Physical Palladium Shares ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| GILD | PALL | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $37.18 |
52-Week Low | $108.22 | $19.96 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
PALL trades at $23.13, down 2.41% over 24 hours amid broader precious metals volatility. The technical outlook is bullish based on moving averages, with neutral oscillators suggesting potential consolidation. Recent news highlights palladium's underperformance relative to gold and silver, creating what some analysts view as a buying opportunity. The ETF underwent a 5-for-1 forward stock split effective May 18, 2026, which adjusted share count without changing the fund's total value.
The outlook for PALL hinges on palladium's supply-demand dynamics and industrial usage. While technical indicators suggest near-term strength, investors face risks from Federal Reserve policy uncertainty and fluctuating industrial demand. Analyst sentiment remains cautiously optimistic given the metal's significant price decline from recent highs, positioning the ETF for potential recovery if macroeconomic conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
